Corporate News – State Street Global Advisors’ SPDR S&P /ASX 50 ETF Update

The State Street Global Advisors, Australia Services Limited, released its daily fund update for July 8 and 9, 2026. The notice confirms that the number of units in issue for the State Street® SPDR® S&P® /ASX 50 ETF remained unchanged, totaling just over nine million units on both reporting days. This stability reflects the ETF’s consistent investor base and a lack of significant creation or redemption activity during the period.

Net Asset Value and Cash Component

  • Net Asset Value (NAV) per unit: The NAV hovered in the mid‑seventies Australian dollars, indicating a stable valuation of the ETF’s underlying basket of 50 Australian shares.
  • Cash component per creation unit: The cash balance was modest, falling below $40 AUD. The low cash level demonstrates a close alignment between the ETF’s NAV and the market value of its underlying holdings, suggesting efficient management of the creation/redemption process.

Portfolio Composition – Focus on Healthcare

Within the ASX 50 index, Sigma Healthcare Ltd holds the fourth‑largest position, following Sonic Healthcare and preceding Sol and WBC. The fund held 5,188 shares of Sigma Healthcare on both reporting days, underscoring the company’s continued significance within the index. Although the update does not provide a price change for Sigma Healthcare, its stable share count and continued inclusion reinforce its status as a heavily weighted constituent of the ETF.

Investor Flows and Market Dynamics

  • Applications/Redemptions: No applications or redemptions were reported over the two days, indicating a period of relative stability in investor flows.
  • Market Impact: The lack of significant changes in unit numbers, NAV, or cash component suggests that the ETF was not subjected to major market events or shifts in investor sentiment during this brief window.

Implications for Stakeholders

  • Investors: The unchanged unit count and stable NAV provide reassurance of the ETF’s liquidity and management efficiency.
  • Healthcare Sector: Sigma Healthcare’s reinforced position highlights ongoing investor confidence in the Australian healthcare market, which may influence future valuation and investment decisions within the sector.
  • Regulatory and Compliance: The update’s transparency aligns with regulatory expectations for disclosure of fund performance and composition, supporting investor trust and market integrity.

Overall, the July 8–9, 2026 update demonstrates a steady state for the State Street® SPDR® S&P® /ASX 50 ETF, with Sigma Healthcare maintaining its key role in the index and no significant market events impacting the fund during this reporting period.